Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study
Trial Parameters
Brief Summary
Pneumonia are the most frequent infections in ICU. Little is known about beta-lactam doses necessary for this infection for patients treated with continuous veino-veinous hemodialysis. The pharmacokinetic variability expose to over and underdosage leading to toxicity or therapeutic failure. The aim of this study is to define if beta-lactams doses used in pneumonia for patients with acute kidney injury treated with our hemodialysis conditions lead to beta-lactam therapeutic plasma levels.
Eligibility Criteria
Inclusion Criteria: * Aged ≥ 18 years * Receiving intraveinous beta-lactam : amoxicillin, amoxicillin-clavulanic acid, piperacillin-tazobactam, cefotaxime, ceftazidime, cefepime, meropenem, imipenem * With AKI defined as any of the following, and treated with Multifiltrate Ci-Ca CVVHD 1000® kit with a dialysis dose of 25 ml/kg/h : * Increase in creatininemia ≥ 0.3 mg/dl (≥ 26.5 µmol/l) within 48 hours * Increase in creatininemia ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days * Urine volume \< 0.5 ml/kg/h for 6 hours * Hospitalized in ICU * Presence of a catheter to facilitate sample collection * With pneumonia defined as any of the following : * Chest X-ray pneumonia : opacities, new or progressive infiltrates * AND at least one of the following : hyperthermia \> 38°C or hypothermia \< 36°C with no other explanation ; leukopenia \< 4 G/L ou leukocytosis \> 12G/L * AND at least one of the following : new onset purulent sputum or change in sputu